Valerio Gelfo
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy.
Journal: NPJ precision oncology
Published: October 31, 2025
The therapeutic exploitation of IL-1 in cancer: Controlling tumor progression and resistance to targeted therapies.
Journal: Seminars in immunology
Published: October 24, 2025
NF-kB oscillation profiles decode response to anti-EGFR monoclonal antibodies.
Journal: SLAS discovery : advancing life sciences R & D
Published: September 28, 2024
Decoding Ribosome Heterogeneity: A New Horizon in Cancer Therapy.
Journal: Biomedicines
Published: December 19, 2023
Aberrant MET activation impairs perinuclear actin cap organization with YAP1 cytosolic relocation.
Journal: Communications biology
Published: December 17, 2022
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy.
Journal: Frontiers in cell and developmental biology
Published: October 29, 2022
Senescence-associated reprogramming induced by interleukin-1 impairs response to EGFR neutralization.
Journal: Cellular & molecular biology letters
Published: October 21, 2021
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 21, 2021
Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies.
Journal: International journal of molecular sciences
Published: July 11, 2020
Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies.
Journal: Journal of clinical medicine
Published: April 08, 2019
Last Updated: 09/26/2026